Phospho-RYR2 (S2808) Antibody

What is RyR2 and why is phosphorylation at S2808 significant?

RyR2 (Ryanodine Receptor 2) is a cardiac muscle calcium release channel with a molecular weight of approximately 565 kDa that plays a crucial role in cardiac excitation-contraction coupling. The phosphorylation of RyR2 at serine 2808 (S2808) has been identified as a potential regulatory mechanism affecting channel activity and cardiac function. This site was the first RyR2-residue identified as a phosphorylation site and is believed to be the primary target of protein kinase A (PKA)-mediated phosphorylation . The degree of steady-state phosphorylation of this site depends on a dynamic balance between multiple protein kinases and phosphatases, allowing precise control of RyR2 activity . Alterations in RyR2-phosphorylation, particularly at S2808, have been implicated in various cardiac diseases, including heart failure and cardiac arrhythmias.

What are Phospho-RYR2 (S2808) antibodies and how do they work?

Phospho-RYR2 (S2808) antibodies are immunological reagents specifically designed to detect RyR2 protein only when phosphorylated at serine 2808. These antibodies are typically produced by immunizing rabbits with synthetic phosphopeptides derived from human RyR2 around the phosphorylation site of Ser2808 . The resulting polyclonal antibodies are then affinity-purified using phospho-specific peptides, and in some cases, antibodies against non-phosphorylated peptides are removed by chromatography to enhance specificity . This rigorous purification ensures the antibody detects only the phosphorylated form of RyR2 at S2808, making it a valuable tool for studying the phosphorylation status of this site in research contexts.

What are the recommended applications for Phospho-RYR2 (S2808) antibodies?

Phospho-RYR2 (S2808) antibodies are validated for several experimental applications:

• Immunohistochemistry (IHC): Typically used at dilutions of 1:50-1:300 to visualize phosphorylated RyR2 in tissue sections

• ELISA (Enzyme-Linked Immunosorbent Assay): Generally used at dilutions around 1:1000-1:10000

• Western Blotting (WB): Used to detect the ~565 kDa phosphorylated RyR2 protein in cell or tissue lysates

• Immunofluorescence (IF): For cellular localization studies of phosphorylated RyR2

The optimal working dilution varies between applications and should be determined empirically for each experimental setup. Most commercially available antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide at concentrations of approximately 1 mg/ml .

How should samples be prepared for optimal detection of phosphorylated RyR2?

Effective detection of phosphorylated RyR2 requires careful sample preparation to preserve the phosphorylation state:

• Tissue samples: Harvest tissues rapidly and flash-freeze in liquid nitrogen or immediately fix in appropriate fixatives (such as paraformaldehyde for IHC). Add phosphatase inhibitors to all buffers to prevent dephosphorylation during sample preparation.

• Cell lysates: Use lysis buffers containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) and protease inhibitors. Keep samples cold throughout processing.

• Protein extraction: For large proteins like RyR2 (~565 kDa), use gentle extraction methods that preserve protein integrity while effectively solubilizing membrane-associated proteins.

• Sample storage: Store phosphorylated protein samples at -80°C and avoid repeated freeze-thaw cycles, as these can lead to protein degradation and loss of phosphorylation .

How can researchers validate the specificity of Phospho-RYR2 (S2808) antibodies?

Validating phospho-specific antibody specificity is crucial for reliable experimental results. Several approaches are recommended:

• Phosphatase treatment controls: Treating a portion of your samples with lambda phosphatase to remove phosphate groups should eliminate or significantly reduce the signal from a truly phospho-specific antibody.

• Phospho-blocking peptide competition: Pre-incubating the antibody with the phosphorylated peptide immunogen should abolish specific binding to the target.

• Genetic models: Using tissues or cells from RyR2-S2808A knock-in mice (where serine 2808 is mutated to alanine, preventing phosphorylation) can serve as negative controls .

• Stimulation experiments: Comparing samples treated with PKA activators (like isoproterenol or forskolin) to demonstrate increased phosphorylation versus samples treated with PKA inhibitors.

• Multiple antibody validation: Using alternative antibodies from different suppliers targeting the same phosphorylation site to confirm results .

What are common pitfalls when working with large proteins like phosphorylated RyR2?

Working with large proteins like RyR2 (~565 kDa) presents several technical challenges:

• Inefficient transfer in Western blotting: Large proteins transfer poorly using standard protocols. Use specialized transfer conditions such as extended transfer times, lower voltage, partial gel digestion techniques, or specialized transfer systems designed for high molecular weight proteins.

• Protein degradation: RyR2 is susceptible to proteolysis. Always use fresh protease inhibitors in all buffers and handle samples quickly at cold temperatures.

• Non-specific binding: Large proteins provide many potential epitopes for non-specific antibody binding. Optimize blocking conditions and consider using specialized blocking reagents designed for phospho-proteins.

• Quantification challenges: The high molecular weight of RyR2 can make accurate quantification difficult. Consider using appropriate loading controls and normalization methods specific for large membrane proteins.

• Phosphorylation dynamics: Phosphorylation states can change rapidly during sample preparation. Rapid tissue harvesting and immediate addition of phosphatase inhibitors are essential for preserving the in vivo phosphorylation state.

How should researchers interpret contradictory findings regarding RyR2-S2808 phosphorylation in heart failure?

The role of RyR2-S2808 phosphorylation in heart failure represents one of the most significant controversies in cardiovascular research. When interpreting contradictory findings, researchers should consider:

• Methodological differences: Different antibodies, phosphorylation detection methods, sample preparation protocols, and experimental models may contribute to divergent results .

• Genetic background effects: Initial studies suggested genetic background might explain contradictory findings between research groups, though later studies with congenic C57Bl/6J mice carrying the S2808A mutation showed this may not be the primary factor .

• Kinase specificity overlap: S2808 may be phosphorylated by kinases other than PKA. Similarly, PKA may phosphorylate additional sites on RyR2 (like S2031), complicating interpretation .

• Temporal dynamics: The phosphorylation state of RyR2 may change during different stages of heart failure. Some studies suggest both S2808 and S2814 are hyperphosphorylated during compensated cardiac hypertrophy, whereas only S2814 remained phosphorylated in end-stage heart failure .

• Multiple post-translational modifications: Recent studies revealed that oxidation and/or S-nitrosylation, together with RyR2-phosphorylation at S2808, may be required to affect channel function, suggesting a more complex regulatory system than initially proposed .

A comprehensive approach incorporating multiple methodologies, careful controls, and consideration of these factors is essential for advancing understanding in this controversial area.

What methodological approaches can help resolve the S2808 phosphorylation controversy?

To address the ongoing controversy surrounding RyR2-S2808 phosphorylation's role in cardiac physiology and pathology, researchers should consider:

• Standardized protocols: Developing and adhering to standardized experimental protocols across research groups for:

  • Sample preparation and phosphorylation preservation

  • Antibody validation procedures

  • Experimental models of heart failure

  • Data analysis and interpretation

• Multi-site phosphorylation analysis: Simultaneously examining multiple phosphorylation sites (S2808, S2814, S2031) to understand potential crosstalk and compensatory mechanisms .

• Comprehensive animal models: Using multiple genetic models including:

  • S2808A knock-in (preventing phosphorylation)

  • S2808D knock-in (phosphomimetic)

  • Combined mutations of multiple phosphorylation sites

  • Tissue-specific and inducible genetic modifications

• Human tissue validation: Studying phosphorylation patterns in human heart samples from patients with different etiologies and stages of heart failure, with careful attention to sample collection and preservation methods .

• Advanced methodologies: Implementing mass spectrometry-based approaches for unbiased quantification of phosphorylation stoichiometry and site occupancy as a complement to antibody-based methods.

How do phosphorylation dynamics at S2808 interact with other post-translational modifications of RyR2?

Research indicates complex interactions between S2808 phosphorylation and other RyR2 modifications:

• Cross-talk with S2814 phosphorylation: Enhanced S2814 phosphorylation has been observed in S2808A knock-in mice, suggesting the phosphorylation state of one residue might affect neighboring residues, particularly following adrenergic stimulation . This indicates potential compensatory mechanisms when one phosphorylation site is altered.

• Redox modifications and phosphorylation: Oxidation and/or S-nitrosylation, together with RyR2-phosphorylation at S2808, may be required for certain functional effects, such as dissociating FKBP12.6 from RyR2 and increasing RyR2 open probability . The exact mechanisms underlying this synergy remain unknown.

• Multiple kinase involvement: While S2808 is considered primarily a PKA target and S2814 a CaMKII target, this specificity is not absolute. Multiple kinases may phosphorylate each site, and other serine/threonine protein kinases can also modify RyR2 .

• Pathophysiological context: Different etiologies of heart failure might affect the relative phosphorylation levels of different RyR2 sites differently. Metabolic syndrome, diabetes, and ischemia (oxidative stress) may impact RyR2 phosphorylation patterns in unique ways that require further investigation .

Understanding these complex interactions requires sophisticated experimental approaches that simultaneously monitor multiple post-translational modifications.

What emerging technologies might improve phosphorylated RyR2 research?

Several cutting-edge technologies show promise for advancing phosphorylated RyR2 research:

• Proximity labeling approaches: Techniques like BioID or APEX can identify proteins that interact with RyR2 specifically when phosphorylated at S2808, potentially revealing phosphorylation-dependent interaction networks.

• Phosphoproteomics with parallel reaction monitoring (PRM): This targeted mass spectrometry approach allows precise quantification of specific phosphopeptides, enabling more accurate measurement of RyR2 phosphorylation stoichiometry at multiple sites simultaneously.

• Cryo-electron microscopy: Advanced structural studies of phosphorylated versus non-phosphorylated RyR2 may reveal how phosphorylation alters channel conformation and function at the molecular level.

• CRISPR-based phosphorylation reporters: Developing cellular systems where phosphorylation events trigger detectable signals could enable real-time monitoring of RyR2 phosphorylation dynamics in living cells.

• Optical electrophysiology: Combining phosphorylation-specific sensors with voltage or calcium indicators could enable simultaneous monitoring of RyR2 phosphorylation status and functional outcomes in intact cells.

How might understanding RyR2-S2808 phosphorylation lead to therapeutic interventions?

Despite the controversies surrounding RyR2-S2808 phosphorylation, this research area holds potential for therapeutic development:

• Targeted phosphorylation modulators: Developing compounds that specifically modify RyR2 phosphorylation at S2808 without affecting other PKA targets could offer precision approaches to modulating calcium handling in heart failure.

• Combinatorial approaches: Therapies targeting multiple post-translational modifications simultaneously (phosphorylation plus redox modifications) might prove more effective than single-target approaches.

• Biomarker development: Phosphorylated RyR2 could serve as a biomarker for cardiac disease progression or treatment response, potentially guiding personalized therapeutic strategies.

• Gene therapy approaches: Advanced delivery methods might enable targeted expression of phosphorylation-resistant (S2808A) or phosphomimetic (S2808D) RyR2 variants in specific cardiac regions for localized modulation of calcium handling.

• Small molecule stabilizers: Development of drugs that specifically bind phosphorylated RyR2 to modulate its activity might provide more specific approaches than current anti-arrhythmic strategies.

The ongoing research into the fundamental biology of RyR2 phosphorylation, despite current controversies, continues to expand our understanding of cardiac physiology and may ultimately yield novel therapeutic approaches for heart failure and arrhythmias.

Table 1: Commonly Available Phospho-RYR2 (S2808) Antibodies and Their Specifications